(NASDAQ: PRAX) Praxis Precision Medicines's forecast annual revenue growth rate of 118.31% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.38%, and it is also forecast to beat the US market's average forecast revenue growth rate of 10.2%.
Praxis Precision Medicines's revenue in 2025 is $8,122,000.On average, 2 Wall Street analysts forecast PRAX's revenue for 2025 to be $67,238,010, with the lowest PRAX revenue forecast at $61,106,946, and the highest PRAX revenue forecast at $73,369,073. On average, 3 Wall Street analysts forecast PRAX's revenue for 2026 to be $1,550,710,969, with the lowest PRAX revenue forecast at $128,426,432, and the highest PRAX revenue forecast at $3,157,192,210.
In 2027, PRAX is forecast to generate $1,542,135,627 in revenue, with the lowest revenue forecast at $261,537,729 and the highest revenue forecast at $3,612,846,337.